| Name | Tadalafil |
| Description | Tadalafil (IC-351) is a carboline-based compound with vasodilatory activity that selectively inhibits the cyclic guanosine monophosphate (cGMP)-specific type 5 phosphodiesterase (PDE-5), preventing cGMP degradation in the smooth muscle of the corpus cavernosa and corpus spongiosum of the penis, thereby causing prolonged muscle relaxation, vasodilation, and enhanced penile erection. |
| In vitro | Tadalafil (at doses of 2 or 10 mg/kg) significantly promotes neural function recovery and increases both cerebral vascular density and the percentage of BrdU-positive endothelial cells. In rats undergoing sham surgery, Tadalafil (at a dose of 2 mg/kg) almost completely restored penile tissue oxygenation and countered the increase induced by nerve transection, while substantially enhancing the muscle/fiber ratio in certain penile tissue sections. When administered to the rat brain, Tadalafil selectively elevated cGMP levels rather than cyclic adenosine monophosphate. Furthermore, Tadalafil reduced the number of apoptotic cells in rats and increased the phosphorylation of kinase Akt and extracellular signal-regulated kinases 1/2 (two survival-related kinases). |
| In vivo | When acting on human hepatocytes, Tadalafil (1 mM) notably increases the expression of CYP3A proteins. Tadalafil can bind to type 5 phosphodiesterase (PDE5) with a dissociation constant (KD) of 2.4 nM, and this binding is stimulated by cyclic guanosine monophosphate (cGMP). |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 3.89 mg/mL (10 mM), Sonication is recommended.
|
| Keywords | Apoptosis | IC 351 | Inhibitor | inhibit | Tadalafil | IC351 | Phosphodiesterase (PDE) |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Acetylcysteine | Myricetin | Sodium 4-phenylbutyrate | L-Ascorbic acid | Dextran sulfate sodium salt (MW 4500-5500) | Metronidazole | Sorafenib | Tributyrin |
| Related Compound Libraries | Highly Selective Inhibitor Library | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
United States
